Research in the Janet Record Lab focuses on medical education and patient-centered care. We’re currently developing a curriculum for internal medicine residents in the inpatient general medicine service setting. The curriculum teaches residents to use hand-carried ultrasound for imaging the inferior vena cava to assess volume status.

Dr. Zhou's research focuses on developing new in vivo MRI and MRS methodologies to study brain function and disease. His most recent work includes absolute quantification of cerebral blood flow, quantification of functional MRI, high-resolution diffusion tensor imaging (DTI), magnetization transfer mechanism, development of chemical exchange saturation transfer (CEST) technology, brain pH MR imaging, and tissue protein MR imaging. Notably, Dr. Zhou and his colleagues invented the amide proton transfer (APT) approach for brain pH imaging and tumor protein imaging. His initial paper on brain pH imaging was published in Nature Medicine in 2003 and his most recent paper on tumor treatment effects was published in Nature Medicine in 2011. A major part of his current research is the pre-clinical and clinical imaging of brain tumors, strokes, and other neurologic disorders using the APT and other novel MRI techniques. The overall goal is to achieve the MRI contrast at the protein and peptide level without injection of exogenous agents and improve the diagnostic capability of MRI and the patient outcomes.

The long-term goal of the Caren L. Freel Meyers Laboratory is to develop novel approaches to kill human pathogens, including bacterial pathogens and malaria parasites, with the ultimate objective of developing potential therapeutic agents. Toward this goal, we are pursuing studies of bacterial isoprenoid biosynthetic enzymes comprising the methylerythritol phosphate (MEP) pathway essential in many human pathogens. Studies focus on understanding mechanism and regulation in the pathway toward the development of selective inhibitors of isoprenoid biosynthesis. Our strategies for creating new anti-infective agents involve interdisciplinary research in the continuum of organic, biological and medicinal chemistry. Molecular biology, protein expression and biochemistry, and synthetic chemistry are key tools for our research.

A. Laboratory activities include the use of accelerator mass spectrometry (AMS) techniques to measure intracellular drugs and drugs metabolites. AMS is a highly sensitive method for detecting tracer amounts of radio-labeled molecules in cells, tissues, and body fluids. We have been able to measure intracellular zidovudine triphosphate (the active anabolite of zidovudine) in peripheral blood mononuclear cells from healthy volunteers given small doses of 14C-zidovudine, and have directly compared the sensitivity of AMS to traditional LC/MS methods carried out in our laboratory. B. Clinical research activities investigate the clinical pharmacology of new anti-HIV therapies and drug combinations. Specific drug classes studied include HIV reverse transcriptase inhibitors, protease inhibitors, entry inhibitors (selective CCR5 and CXCR4 antagonists), and integrase inhibitors. Scientific objectives of clinical studies include characterization of early drug activity, toxicity, and pharmacokinetics. Additional objectives are characterization of pathways of drug metabolism, and identification of clinically significant harmful and beneficial drug interactions mediated by hepatic and intestinal cytochrome P450 isoforms.

The Peter van Zijl Laboratory focuses on developing new methodologies for using MRI and magnetic resonance spectroscopy (MRS) to study brain function and physiology. In addition, we are working to understand the basic mechanisms of the MRI signal changes measured during functional MRI (fMRI) tests of the brain. We are also mapping the wiring of the brain (axonal connections between the brains functional regions) and designing new technologies for MRI to follow where cells are migrating and when genes are expressed. A more recent interest is the development of bioorganic biodegradable MRI contrast agents. Our ultimate goal is to transform these technologies into fast methods that are compatible with the time available for multi-modal clinical diagnosis using MRI.

The lab’s assets include three MRI systems available for pediatric studies, cardiac imaging processing, cardiovascular imaging and therapeutic ultrasound. A robust echocardiogram program conducts 10,000 transthoracic echocardiograms and 1,300 fetal echocardiograms per year, and maintains a database with 10 years of data.

Research in the Peter Abadir Lab focuses on the renin-angiotensin system (RAS), a signaling pathway that regulates blood pressure and has been linked independently to both aging and inflammation. We’re particularly interested in changes in RAS that occur with aging. We also study signal transduction and the role of the crosstalk between angiotensin II receptor in aging and are interested in understanding the function of angiotensin II in the process of vascular aging.

The Center on Aging and Health pursues creative approaches to solve the important health and health care problems for an aging population. Research in our center involves population-based and clinical studies of the causes, correlates, and consequences of aging-related conditions, including frailty, disability, and social isolation. We house four distinct research working groups: the Frailty and Multisystem Dysregulation Working Group; the Family and Social Resources Working Group; the Cognitive and Sensory Functions Working Group; and the Biostatistics, Design and Analysis Working Group. We provide key infrastructure, such as the statistical data core, that supports clinical- and population-based research and education with expertise in research with older adults.